Affordable Access

Access to the full text

Health-Related Quality of Life as a Prognostic Measure of Clinical Outcomes in Renal Cell Carcinoma: A Review of the CheckMate 025 Trial

Authors
  • Grimm, Marc-Oliver1
  • Grünwald, Viktor2
  • 1 Jena University Hospital, Department of Urology, Jena, Germany , Jena (Germany)
  • 2 Medical School Hannover (MHH), Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover, Germany , Hannover (Germany)
Type
Published Article
Journal
Oncology and Therapy
Publisher
Springer Healthcare
Publication Date
Mar 23, 2017
Volume
5
Issue
1
Pages
75–78
Identifiers
DOI: 10.1007/s40487-017-0042-6
Source
Springer Nature
Keywords
License
Green

Abstract

The phase III, randomized, open-label CheckMate 025 study showed an overall survival benefit in patients with advanced renal cell carcinoma treated with nivolumab versus everolimus. Here, we review the health-related quality of life (HRQoL) results of this trial, in which nivolumab was associated with significant improvements in HRQoL, with more patients having a clinically meaningful HRQoL improvement and a shorter time to onset of improvement compared with everolimus. Further exploratory analysis suggests a positive correlation between baseline HRQoL scores and overall survival. These results support the use of HRQoL as a valuable measure of patient perspective that could translate into better clinical outcomes and should be taken into account during treatment selection.

Report this publication

Statistics

Seen <100 times